PARP Inhibitors Could Help More Breast Cancer Patients than Previously Thought, U.K. Study Suggests

PARP Inhibitors Could Help More Breast Cancer Patients than Previously Thought, U.K. Study Suggests
PARP inhibitors like Lynparza (olaparib) were designed to treat patients with inherited BRCA1 or BRCA2 mutations, but more women with breast cancer could benefit from these drugs, a study suggests. The study, “HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures,” appeared in Nature Medicine. It argues that women with BRCA

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *